Clinical improvement in a patient with neuromyelitis optica following therapy with the anti-IL-6 receptor monoclonal antibody tocilizumab

Neuromyelitis optica (NMO) is a disabling autoimmune disease associated with an elevation of anti-aquaporin 4 (AQP4) autoantibodies. Here, we present a case with NMO who responded to monthly administration of the anti-IL-6 receptor antibody tocilizumab. The treatment rapidly reduced the elevated num...

Descripción completa

Detalles Bibliográficos
Autores principales: Araki, Manabu, Aranami, Toshimasa, Matsuoka, Takako, Nakamura, Masakazu, Miyake, Sachiko, Yamamura, Takashi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Japan 2012
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3713263/
https://www.ncbi.nlm.nih.gov/pubmed/22782533
http://dx.doi.org/10.1007/s10165-012-0715-9
_version_ 1782277164332220416
author Araki, Manabu
Aranami, Toshimasa
Matsuoka, Takako
Nakamura, Masakazu
Miyake, Sachiko
Yamamura, Takashi
author_facet Araki, Manabu
Aranami, Toshimasa
Matsuoka, Takako
Nakamura, Masakazu
Miyake, Sachiko
Yamamura, Takashi
author_sort Araki, Manabu
collection PubMed
description Neuromyelitis optica (NMO) is a disabling autoimmune disease associated with an elevation of anti-aquaporin 4 (AQP4) autoantibodies. Here, we present a case with NMO who responded to monthly administration of the anti-IL-6 receptor antibody tocilizumab. The treatment rapidly reduced the elevated numbers of plasmablasts and anti-AQP4 autoantibodies in the patient. Furthermore, neuropathic pain and disability scores gradually improved. Tocilizumab may be considered as a therapeutic option for NMO.
format Online
Article
Text
id pubmed-3713263
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher Springer Japan
record_format MEDLINE/PubMed
spelling pubmed-37132632013-08-15 Clinical improvement in a patient with neuromyelitis optica following therapy with the anti-IL-6 receptor monoclonal antibody tocilizumab Araki, Manabu Aranami, Toshimasa Matsuoka, Takako Nakamura, Masakazu Miyake, Sachiko Yamamura, Takashi Mod Rheumatol Case Report Neuromyelitis optica (NMO) is a disabling autoimmune disease associated with an elevation of anti-aquaporin 4 (AQP4) autoantibodies. Here, we present a case with NMO who responded to monthly administration of the anti-IL-6 receptor antibody tocilizumab. The treatment rapidly reduced the elevated numbers of plasmablasts and anti-AQP4 autoantibodies in the patient. Furthermore, neuropathic pain and disability scores gradually improved. Tocilizumab may be considered as a therapeutic option for NMO. Springer Japan 2012-07-11 2013-07 /pmc/articles/PMC3713263/ /pubmed/22782533 http://dx.doi.org/10.1007/s10165-012-0715-9 Text en © Japan College of Rheumatology 2012
spellingShingle Case Report
Araki, Manabu
Aranami, Toshimasa
Matsuoka, Takako
Nakamura, Masakazu
Miyake, Sachiko
Yamamura, Takashi
Clinical improvement in a patient with neuromyelitis optica following therapy with the anti-IL-6 receptor monoclonal antibody tocilizumab
title Clinical improvement in a patient with neuromyelitis optica following therapy with the anti-IL-6 receptor monoclonal antibody tocilizumab
title_full Clinical improvement in a patient with neuromyelitis optica following therapy with the anti-IL-6 receptor monoclonal antibody tocilizumab
title_fullStr Clinical improvement in a patient with neuromyelitis optica following therapy with the anti-IL-6 receptor monoclonal antibody tocilizumab
title_full_unstemmed Clinical improvement in a patient with neuromyelitis optica following therapy with the anti-IL-6 receptor monoclonal antibody tocilizumab
title_short Clinical improvement in a patient with neuromyelitis optica following therapy with the anti-IL-6 receptor monoclonal antibody tocilizumab
title_sort clinical improvement in a patient with neuromyelitis optica following therapy with the anti-il-6 receptor monoclonal antibody tocilizumab
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3713263/
https://www.ncbi.nlm.nih.gov/pubmed/22782533
http://dx.doi.org/10.1007/s10165-012-0715-9
work_keys_str_mv AT arakimanabu clinicalimprovementinapatientwithneuromyelitisopticafollowingtherapywiththeantiil6receptormonoclonalantibodytocilizumab
AT aranamitoshimasa clinicalimprovementinapatientwithneuromyelitisopticafollowingtherapywiththeantiil6receptormonoclonalantibodytocilizumab
AT matsuokatakako clinicalimprovementinapatientwithneuromyelitisopticafollowingtherapywiththeantiil6receptormonoclonalantibodytocilizumab
AT nakamuramasakazu clinicalimprovementinapatientwithneuromyelitisopticafollowingtherapywiththeantiil6receptormonoclonalantibodytocilizumab
AT miyakesachiko clinicalimprovementinapatientwithneuromyelitisopticafollowingtherapywiththeantiil6receptormonoclonalantibodytocilizumab
AT yamamuratakashi clinicalimprovementinapatientwithneuromyelitisopticafollowingtherapywiththeantiil6receptormonoclonalantibodytocilizumab

Ejemplares similares